Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2015-09-02 M&A Activity
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB to sell its U.S. specialty generics business Kremers Urban to Lannett for US$ 1.23 billion in cash plus contingent payments
M&A Activity Classification · 99% confidence The document is a press release announcing a definitive agreement for UCB to sell its U.S. specialty generics subsidiary, Kremers Urban, to Lannett for a specified cash amount plus contingent payments. It details the strategic rationale (focus on core CNS/immunology business) and the intended use of proceeds (debt reduction). The text is clearly an announcement regarding a major corporate transaction, specifically a divestiture/sale of a business unit. This fits best under the category of M&A Activity (TAR), as a divestiture is a form of M&A transaction. It is not a standard financial report (10-K, IR, ER) or a general regulatory filing (RNS), but a specific corporate action announcement.
2015-09-02 English
UCB vend Kremers Urban, sa division spécialisée dans les génériques, à Lannett, pour un montant de US$ 1,23 milliards en espèces plus une contrepartie conditionnelle
M&A Activity Classification · 100% confidence The document is a press release announcing a definitive agreement for the sale of UCB's generic division, Kremers Urban, to Lannett Company for US$ 1.23 billion. This is a clear announcement of a merger and acquisition (M&A) transaction. According to the filing definitions, documents related to merger proposals or takeover bids are classified as TAR.
2015-09-02 French
UCB verkoopt Kremers Urban, gespecialiseerd in generische geneesmiddelen, aan Lannett voor US$ 1,23 miljard cash plus voorwaardelijke betalingen
M&A Activity Classification · 99% confidence The document is a press release dated September 2, 2015, announcing a significant corporate transaction: the sale of UCB's generics subsidiary (Kremers Urban) to Lannett for a specific cash amount plus contingent payments. This type of announcement, detailing a major corporate action like an acquisition or divestiture, falls under the category of Mergers & Acquisitions (M&A) activity. The defined code for M&A Activity is TAR (Takeover/Acquisition/Restructuring). Although it is a press release, its core content is the transaction itself, making TAR more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length (6836 chars) is substantial enough to contain the details of the deal rather than just announcing an attachment.
2015-09-02 Dutch
UCB HY results 2015 ENG.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'UCB 2015 Half Year Report' and contains detailed financial performance data, including revenue, net sales, EBITDA, and net profit for the six-month period ending June 30, 2015. It includes comprehensive financial tables and management commentary on business trends. Although it mentions that a 'full financial report' is available on the website, the document itself provides substantive financial data and analysis, qualifying it as an Interim/Quarterly Report (IR) rather than a mere announcement (RPA). H1 2015
2015-07-31 Dutch
UCB HY results 2015 FR.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for UCB for the first half of 2015. It contains detailed financial statements, key performance indicators, management commentary on business trends, R&D updates, and a summary table of financial results. It is not merely an announcement, as it provides substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. H1 2015
2015-07-31 Dutch
UCB HY results 2015 NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive half-year financial report for UCB for the period ending June 30, 2015. It contains detailed financial statements, performance analysis, R&D updates, and financial outlooks. Although it mentions that the full report is available on their website, the document itself provides substantive financial data and analysis, qualifying it as an Interim/Quarterly Report (IR) rather than just a publication announcement. H1 2015
2015-07-31 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.